Science & technology

Science & technology

Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.

Overview

Our pipeline

Matrix-M™ adjuvant

Recombinant protein-based nanoparticle vaccine

Global vaccine authorization / approval map

COVID-19 UPDATES

Novavax has demonstrated its ability to quickly produce viable vaccine candidates for emerging infectious diseases such as COVID-19.

Learn more about our COVID-19 updates
Who we are

Who we are

We are a biotechnology company committed to help address serious infectious disease globally through the discovery, development, and delivery of innovative vaccines to patients around the world.

Our company

Executive leadership

Senior management team

Board of directors

Our partners

Build your future with us

Join other passionately curious people who are bringing innovative vaccines to the world

Discover career opportunities
Insights

Insights

Novavax is committed to accelerating the development of new and promising vaccines by building on years of study and experience.

Articles

Diversity matters: Inclusivity in clinical trials

From pandemic to endemic: Why COVID-19 may be here to stay

Standing on the shoulders of giants: How a Novavax vaccine is developed

Investor Hub

Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases.

Latest investor presentation

Latest clinical presentation

Latest clinical presentation
(2.4 MB)

Latest quarterly earnings

Latest quarterly earnings
(3.4 MB)

Annual report

Global ticker

NASDAQNVAX

Latest press releases Events & presentation Reports & financials SEC filings Stock details & analyst coverage

Recent News

May 13, 2022

Novavax Files for Emergency Use Authorization of COVID-19 Vaccine in Taiwan

Novavax today announced the submission of a request for emergency use authorization to Taiwan’s Food and Drug Administration for its COVID-19 vaccine, NVX-CoV2373, for active immunization...

Learn more

May 9, 2022

Novavax Reports First Quarter 2022 Financial Results and Operational Highlights

Achieved revenue of $704 million and net income of $203 million highlighting the first profitable quarter as a commercial stage company Reiterating full year 2022 total revenue guidance of between...

Learn more

May 6, 2022

Novavax Submits Variations to Expand Australian and New Zealand Provisional Approval of Nuvaxovid™ COVID-19 Vaccine to Adolescents aged 12 Through 17 Years

Novavax today announced the submission of variations to the Australian Therapeutic Goods Agency (TGA) and Medsafe, the New Zealand Medicines and Medical Devices Safety Authority, to expand the...

Learn more

All press releases

Why invest with us

We are a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases.

Learn more

For much of my four-decade career, I’ve worked with biotech companies trying to solve significant health challenges, including HIV. Novavax is uniquely positioned to help end this pandemic with our protein-based vaccine. I believe in NVX-CoV2373 so much.

I came out of retirement to join the fight.

Lisa Dunkle
Vice President, Global Medical Lead for Coronavirus Vaccine

Governance documents

Novavax board committees

Audit committee charter

Compensation committee charter

Nominating and corporate governance committee charter

Research & development committee charter

Code of business conduct and ethics

Hotline policy

Corporate governance guidelines

Get notifications for investor updates